IntroductionAneurysmal subarachnoid haemorrhage (SAH) is a devastating disease first described in the era of Hippocrates. Despite advances in treatment, 1-month case fatality remains as high as 35 %, with around one-third of survivors needing lifelong care and a further third having residual cognitive impairment that affects functional status and quality of life. The immediate and delayed effects of SAH on outcome have recently been reviewed in Intensive Care Medicine [1]. There have been advances in the treatment of this devastating condition aimed at reducing early (mainly re-bleeding) or late complications, particularly delayed cerebral ischemia (DCI). The importance of treatment in high-volume centres by a multidisciplinary team cannot be over-emphasised [2].Endovascular coiling of intracranial aneurysms represents a major advance in the treatment of SAH and allows minimally invasive and effective treatment. Flow-diverting stents, with or without coils, are an increasingly employed ...